ASX Announcement | 3 December 2020
Noxopharm Limited (ASX:NOX)

Noxopharm Completes A$23 million Placement to Fund Clinical Studies

Highlights:

- Noxopharm successfully raises A$23 million via a Placement, with cornerstone institutional investors coming from Australia, Hong Kong and the USA
- Funds raised will drive two new Veyonda® Phase 2 clinical trials and complete research on European patients experiencing moderate COVID-19-related lung dysfunction
- Key strategic objective is to establish Veyonda® as the standard of care cancer co-treatment, enabling immuno-oncology therapy, radiotherapy, and chemotherapy to reach their full potential
- Placement will strengthen the Company's balance sheet, provide a runway for a series of critical clinical review points in 2021, and support a value-creating drug pipeline
- Placement is not subject to shareholder approval
- Investor Webinar to be held next week to discuss Company's plans for 2021

Sydney 3 December 2020: Australian clinical stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce that it has successfully completed a A$23 million share placement to professional, institutional, and sophisticated investors (**Placement**).

Canaccord Genuity (Australia) Limited acted as Sole Lead Manager and Bookrunner to the Placement.

Noxopharm CEO, Dr Graham Kelly said: "The support received from new, high-quality investors as well as some existing shareholders demonstrates a shared vision in the potential of our technology. That vision is to see Veyonda® become the drug of choice to restore cancer-eradicating immune function to tumours, the so-called cold-to-hot effect. This absence of immune function in most human tumours is now recognised as the primary factor holding back current cancer therapies from working to full effect in most patients. The significance of what we are doing is that Veyonda, with its unique cold-to-hot effect, is the first opportunity medicine has had of seeing whether this problem can be rectified across a range of major cancer types. If Veyonda proves to be the answer we believe it to be, then the face of cancer therapy is set to change in a dramatic way."

The funds raised in this placement are intended to provide sufficient runway to show whether that vision can be realised.

The Company is testing the benefit of the cold-to-hot action across three programs:

- The first is with checkpoint inhibitors. The **IONIC Program** is testing Veyonda in combination with the Bristol Myers-Squibb (NYSE:BMY) immuno-oncology drug, Opdivo®
- The second is with external radiotherapy. The **DARRT Program** is testing Veyonda® in combination with external beam radiotherapy
- The third is with intravenous radiotherapy. The **LuPIN Program** is testing Veyonda in combination with the Novartis (SWX:NOVN) radiopharmaceutical drug, ^{177}Lu-PSMA-617.

"Planning for both IONIC and DARRT studies has been in the works for many months, but this fresh injection of funds will ensure that both studies can start recruiting patients as soon as possible in the new year. When combined with next year's anticipated Federal Government R&D Rebate, we expect to be funded through into 2022."

"I would like to thank existing shareholders for their continued support and to welcome new shareholders to the Company's register, which continues to be strengthened," Kelly added.

Use of Funds

Placement proceeds will be applied to the following activities:

- Commencement of the Phase I/II IONIC-1 study to be conducted in 3 Australian hospitals in 30 patients with a variety of late-stage cancers
- Commencement of the Phase II DARRT-2 multinational study to be conducted in up to 200 patients with late-stage prostate, breast or lung cancers
- Completion of the Phase II LuPIN study in 56 men with late-stage prostate cancer
- Completion of the NOXCOVID-1 study in European hospitals in 40 patients experiencing moderate lung dysfunction associated with COVID-19 disease
- Two exciting drug discovery programs intended to supply additional first-in-class pipeline drug candidates in the fields of (i) brain cancer, and (ii) pancreatic and gallbladder cancers.

Placement

42,592,592 shares were placed at A$0.54, representing a 15.6% discount to the 5-day VWAP.

The Placement will be undertaken within the available capacity under Listing Rule 7.1 and 7.1A as outlined in the Appendix 3B.

Timetable

Settlement of the Placement is expected to occur on Wednesday 9 December 2020 with the issue of New Shares expected to occur on Thursday 10 December 2020. The New Shares issued under the Placement will rank *pari passu* with the Company's existing Ordinary Fully Paid Shares on issue, as at their date of issue.

Investor Webinar

Noxopharm is planning an investor webinar for next week. CEO, Dr Graham Kelly, will be providing an overview of the Company's plans and expectations for 2021. Details of the webinar will be announced in the next 24 hours.

Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

-ENDS-

About Noxopharm
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – inhibition of sphingosine kinase and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunotherapy functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking sepsis.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).

To learn more, please visit: noxopharm.com.

Investor & Corporate enquiries:
Prue Kelly
M: +61 459 022 445
E: info@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries
Julia Maguire
The Capital Network
T: + 61 2 8999 3699
E: julia@thecapitalnetwork.com.au

Forward Looking Statements
This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.